期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奥美拉唑药物相互作用案例分析 被引量：3

Case analysis of drug interactions in Omeprazole
下载PDF
导出
摘要 目的探讨奥美拉唑与其他药物同时运用时的相互作用。方法通过本院消化内科在选用奥美拉唑配合其他不同的药物治疗时产生的相互作用6例案例进行分析总结。结果奥美拉唑抑制药效的药物有硫酸亚铁片、地高辛、酮康唑,有强化药效作用的是华法林、卡马西平、甲氨蝶呤。结论奥美拉唑与其他药物合用时,配伍前应了解药物的生化及代谢过程。以免产生药物间相互作用,降低药效或产生毒副作用,影响治疗效果。 Objective To explore the interaction of Omeprazole and other drugs for use at the same time. Methods Six eases with the interaction caused by using Omeprazole combined with other different drugs in Digestion medical department of our hospital were analyzed and summarized. Results Omeprazole could inhihite the efficacy of the drug including Ferrous sulfate tablets, Digoxin, Ketoconazole, and could strengthen the efficacy of the drug including warfarin, Carba- mazepine, Methotrexate. Conclusion The use of Omeprazole combined with other drugs beforeshould be aware of the drug＇s biochemical and metabolic processes, in order to avoid the drug interactions, reduce efficacy, occur side effects and influence the therapeutic effects.
作者 刘雄
机构地区 广东省梅州市人民医院药剂科
出处 《中国当代医药》 2012年第23期255-256,共2页 China Modern Medicine
关键词 奥美拉唑 药物 相互作用 案例分析 Omeprazole Drugs Interaction Case analysis
分类号 R975 [医药卫生—药品]
  • 相关文献

参考文献6

二级参考文献31

  • 1张雪丽,王亚宁,惠莉.埃索美拉唑在治疗HP相关性胃炎、十二指肠溃疡中的价值[J].陕西医学杂志,2008,37(10):1377-1378. 被引量：17
  • 2王任之,邓兴臣,黄飞雄,陈村龙,徐健雄,杨柯.雷贝拉唑四联疗法治疗幽门螺杆菌阳性十二指肠溃疡的疗效观察[J].现代消化及介入诊疗,2006,11(2):102-103. 被引量：12
  • 3肖洪斌 贾红.奥美拉唑治疗消化性溃疡的研究进展.中华现代临床医学杂志,2009,7(10):874-876.
  • 4Clissoid SP,Campoli-Richards DM meprazole.A preliminary review of its pharmacodynamic and pharmacokinetic poperties anr therapeutic in patic ulcer disease and Zollinger-Ellison syndrome[J].Drugs,1986;32(7):15.
  • 5Bradford MM.A rapid and sensitive method for the quantitatinn of microgram quantities of protein utilizing the principle of protein-dye binding[J].Anal Biochem,1976; 72(9):248-254.
  • 6Schaifer-Korting M. New systemic antifungal drugs: mechanisms of action, drug interactions and side effects [J]. Mycoses, 2003, 46(Suppl 1):28-31.
  • 7Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole [ J ]. Br J Clin Pharmacol, 2003, 56(Suppl 1) :56-61.
  • 8Mendila M, Waiter GF, Stoll M, et al. Rhabdomyolysis in antiretroviral therapy with Lamivudin [ J]. Dtsch Med Wochenschr, 1997, 122 (33) : 1003-1006.
  • 9Pasqualotto AC, Xavier MO, Andreolla HF, et al. Voriconazole therapeutic drug monitoring: focus on safety [ J ]. Exper Opin Drug Saf, 2010, 9( 1 ) : 125-137.
  • 10Boussaud V, Daudet N, Billaud EM, et al. Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus [ J]. J Heart Lung Transplant, 2008, 27 (2) :229-232.

共引文献45

同被引文献62

  • 1王尚昆. 质子泵抑制剂对华法林抗凝疗效的影响[J] .实用心脑肺血管病杂志,2 0 1 4 ,1 2 (2 3 ) :2 1 3 8 -9 .
  • 2Jung JW , Kang H R , Kwon JW , et a l. The p o ten tia l in hib ito ry effect o f revaprazan, an acid pum p antagonist,on anticoagulation w ith w a rfa rin [J]. Tohoku J Exp Med,2011, 224(4): 2 9 3 -3 0 0 .
  • 3Shirayam a T , S hiraishi H , K uroyanagi A , et a l. In teraction between w arfarin and proton pum p in h ib ito rs[J].J Clin Med, 2014, 5(14): 8 3 6 -4 3 .
  • 4Zhong SL, Y u X Y , L iu Y , et a l. Integrating in te ra ctin gdrugs and genetic variations to im prove the p re d ic ta b ilityo f w arfarin m aintenance dose in Chinese patients[J].Pharmacogenet Genomics, 2012, 22(3): 1 76-82.
  • 5US Food and Drug A d m in istra tio n (FDA). Drugs FDA:FD A approved drug products. [EB/OL]. [2015 -03 -18].http://w w w .accessdata.fda.gov/S cripts/cder/D rugsatFD A.
  • 6Uno T, Sugim oto K , Sugawara K , et a l. The role o fcytochrom e P2C19 in R -w a rfa rin pharm acokinetics andits in te ra ctio n w ith om eprazole [J]. Ther Drug Monit,2008, 30(3): 2 7 6 -8 1 .
  • 7H ata M , Hayasaka M , Sezai A , et a l. Proton pump in hib ito rs may increase the ris k o f delayed bleedingcom plications a fte r open heart surgery i f used concom itan tly w ith w arfarin [J]. Thorac Cardiovasc Surg, 2008,56(5): 2 7 4 -7 .
  • 8Hagym 6si K ,M ttlln e r K ,H ersz6nyi L ,et a l. Update onthe pharm acogenom ics o f proton pum p in h ib ito rs [J],Pharmacogenomics, 2011, 12(6): 8 7 3 -8 8 .
  • 9D adabhai A , Friedenberg F K . Rabeprazole: a pharm acologicand c lin ic a l review fo r a c id -re la te d disorders [J].Expert Opin Drug Scf, 2009, 8(1): 1 1 9-26.
  • 10T eichert M, Van Noord C, U itte rlin d e n AG , et a l.Proton pum p in h ib ito rs and the ris k o f overanticoagulatio n d u rin g acenocoum arol m aintenance treatm ent [J].Br J Haematol, 2011, 153(3): 3 7 9 -8 5 .

引证文献3

二级引证文献51

中国当代医药
2012年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部